Found "Health Policies": 1,084 results
Is diabetes and hypertension screening worthwhile in resource-limited settings? An economic evaluation based on a pilot of a Package of Essential Non-communicable (PEN) disease interventions in Bhutan. (2014)
In response to a lack of cost-effective data on screening and early treatment of diabetes and hypertension in resource-limited settings, a model-based economic evaluation was performed on the World Health Organization (WHO)’s Package of Essential Non-communicable (PEN) disease interventions for prim
Assessing the Accuracy and Feasibility of a Refractive Error Screening Program Conducted by School Teachers in Pre-Primary and Primary Schools in Thailand (2014)
Abstract
Introduction: As part of the development of a system for the screening of refractive error in Thai children, this study describes the accuracy and feasibility of establishing a program conducted by teachers.
Objective: To assess the accuracy and feasibility of screening by teachers.
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand (2014)
Abstract
Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I
Economic Evaluation of 3-Drug Antiretroviral Regimens for the Prevention of Mother-to-Child HIV Transmission in Thailand (2015)
Pitsaphun Werayingyong, BPharm, MSc1, Nittaya Phanuphak, MD2, Kulkunya Chokephaibulkit, MD3, Sripen Tantivess, BPharm, PhD1, Nareeluk Kullert, BSc4, Kakanang Tosanguan, BPharm1, Rukmanee Butchon, MSc1, Nipunporn Voramongkol, MD4, Sarawut Boonsuk, MD5, Songyot Pilasant, BSc1, Wantanee Kulpeng, BSc1,
A store-and-forward telemedicine for retinopathy of prematurity screen: is it cost-effective in Thailand? (2015)
Phanthipha Wongwai a, Pritaporn Kingkaew b, Somkiat Asawaphureekorn a, Tharatip Kolatat c
aDepartment of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40000, Thailand
bHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi 11000, Thailand
cDepartment of Pa
Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. 2015
Thanthima Suwanthawornkul1, Thunyarat Anothaisintawee2*,
Abhasnee Sobhonslidsuk3, Ammarin Thakkinstian4, Yot Teerawattananon1
1 Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand,
2 Department of Family Medicine, Faculty of Medicine, Ramathibodi
Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016
Full text: http://link.springer.com/article/10.1007s40273-015-0360-1
A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines (2016)
Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1
Abstract
Background
For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte
Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
Abstract
BACKGROUND:
Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis
Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia
Abstract
Objectives
This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD)
10 / Page